Last checked at 23 Mar 2023 07:00
23 March 2023
ECO Animal Health Group plc
(''ECO", the "ECO Group") (AIM: EAH)
Pre-close Trading Update
ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to provide an update to its expected results for the year ended 31 March 2023.
The ECO Group has experienced strong trading in its final quarter and it is clear that the demand for Aivlosin has been a little stronger than expected in China and Asia. As a result, the Board now expects that Revenue and Earnings before Interest, Tax, Depreciation and Amortisation will be slightly ahead of market expectations for the current financial year.
David Hallas, CEO, noted that "Our business has delivered good progress in key international markets especially Asia. We look forward to providing a further update following the completion of the financial year."
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR") as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
For further information please contact:
ECO Animal Health Group plc David Hallas (CEO) Christopher Wilks (CFO)
| 020 8447 8899
|
IFC Advisory Graham Herring Zach Cohen
|
020 3934 6630
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies George Tzimas |
020 7496 3000 |
Investec (Joint Broker) Gary Clarence Lydia Zychowska Carlo Spingardi |
020 7597 5970
|
Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.